Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4007460 | 0.98 | APP (0.38) | APPTRPV1KCNH2TDO2KDM1A | |
| SCHEMBL12363690 | 0.85 | TRPV1 (0.38) | APPTRPV1KCNH2TDO2KDM1A | |
| SCHEMBL16065873 | 0.79 | APP (0.50) | APPTRPV1KCNH2MAPT | |
| SCHEMBL26552439 | 0.74 | KCNH2 (0.39) | APPTRPV1KCNH2MAPT | |
| SCHEMBL17471317 | 0.74 | TRPV1 (0.42) | APPTRPV1KCNH2TDO2KDM1A | |
| SCHEMBL27815796 | 0.73 | TRPV1 (0.38) | APPTRPV1KCNH2TDO2KDM1A | |
| SCHEMBL904562 | 0.72 | KMT2A (0.41) | MAPT | |
| SCHEMBL28284779 | 0.71 | TRPV1 (0.42) | APPTRPV1MAP3K11MAPT | |
| SCHEMBL1707922 | 0.69 | NNMT (0.43) | MAPT | |
| SCHEMBL14266228 | 0.69 | APP (0.56) | APPMAP3K11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2356120-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2010038165-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PIK3CA, PIK3CD, PIK3R5 | APP 4226/4885TRPV1 2140/4885KCNH2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.